Нові моноклональні антитіла ІПО-38 до ядерного антигену, що асоційований з проліферацією нормальних та злоякіснотрансформованих клітин: Автореф. дис..

CAAAEUeIA OA?AEOA?ENOEEA ?IAIOE

Aeooaeuei?noue oaie. Caeiiii??iino? i?ioeana i?ie?oa?aoe?? iooeeiieo
ee?oei — iaeei ?c iniiaieo e?eoa???a aeeiai?ee ?icaeoeo ceiye?nieo
iiaiooai?aiue. Oyaeaiiy i?i e?iaoeeo i?ie?oa?aoeaieo i?ioean?a iino?eii
iioe?th?oueny ? ooi/ith?oueny. Aeine?aeaeaiiy inoaii?o ?ie?a eaeooue o
aeaio iai?yieao. Ia?oee — oea aea/aiiy iieaeoey?ieo iaoai?ci?a
i?ie?oa?aoe?? ?c c‘ynoaaiiyi ?ie? ie?aieo ee?oeiieo noanoaioe?e a
?aaoethaaii? oeueiai i?ioeano, a oaeiae aieeao ia iueiai ??cieo
aeciaaiieo ? aiaeiaaiieo oaeoi??a (Pines J. et al., 1995; Brechot C.,
1997). Ae?oaee — aeine?aeaeaiiy iniaeeainoae i?ie?oa?aoe?? iooeeiieo
ee?oei o oai?eo c ??cieie iiaiooai?aiiyie c iaoith aeei?enoaiiy oe???
?ioi?iaoe?? aeey i?iaiicoaaiiy ia?aa?ao caoai?thaaiiy ? ei?aeoe?? noai
oa?ai??. ?nio? ?yae ?ia?o, ?acoeueoaoe yeeo na?ae/aoue i?i iayai?noue
ei?aeyoe?? i?ae ?ioaineai?noth i?ie?oa?aoeaiiai i?ioeano ? ia?aa?aii
caoai?thaaiiy (Eioaeueieeia A.I. e niaao., 1997; O’Relly S.M. et al.,
1992). Oae? aeine?aeaeaiiy aeaee i?aenoaao ?icaeyaeaoe ee?oeiio
i?ie?oa?aoe?th ye i?iaiinoe/iee e?eoa??e i?e iiaiooai?aiiyo ??cii?
eieae?caoe?? ? a?noieia?/ii? no?oeoo?e.

Aei iaaeaaiueiai /ano ?nioaaa ?yae iaoiae?a aeey ioe?iee e?iaoeee
i?ie?oa?aoe??, na?aae yeeo iaoiae aaoi?aae?ia?ao?? c aeei?enoaiiyi
oei?aeeia, iii?/aiiai o?eo??i (Malaise E.P. et al., 1973), i?ioi/ia
oeeoiiao??y c aecia/aiiyi ai?noo AeIE o yae?ao ee?oei (Baisch H. et al.,
1975), ?ii?aaiaoe?y ioeeaie acioiieeneei n??aeii (Busch H. et al.,
1979).

?ic?iaea a?a?eaeiiii? oaoiieia?? io?eiaiiy iiiieeiiaeueieo aioeo?e
(IEAO) (Kohler G., Milstein C., 1975) iaaeaea a/aiei iiaeeea?noue
iaea?aeoaaoe iia? oi?eaeuei? aenieiniaoeeo?/i? ?aaaaioe, ui
aeicaieythoue a?coae?coaaoe ??ci? aioeaaie ye ia iiaa?oi? ee?oei, oae ?
a oeeoiieaci? ? yae?? (Marx U. et al., 1997). Aeaye? c oeeo aioeaai?a
? oeeeeicaeaaeieie, ui aeicaiey? aeei?enoiaoaaoe io?eiai? aei ieo IEAO
aeey aea/aiiy i?ie?oa?aoe?? ii?iaeueieo ? ceiye?niio?ainoi?iiaaieo
ee?oei. Oae, aoee io?eiai? iiiieeiiaeuei? aioeo?ea aei aioeaai?a c
oa?aeoa?iith aeni?an??th o ee?oeiao, ui i?ie?oa?othoue. Na?aae ieo
oe?iei a?aeii? IEAO E?-67 (Gerdes J . et al., 1984), aioeo?ea aei PCNA
(Takasaki Y. et al., 1984), ?aoeaioi?a o?ainoa?eio (Judd W., 1980), AeIE
iie?ia?ac symbol 97 \f «Symbol» \s 12 (Alama A., 1987) oa symbol 100
\f «Symbol» \s 12 (Lee, M.Y., 1989), ye? ciaeoee aeei?enoaiiy ? o
ee?i?/i?e i?aeoeoe?. Aea aeacai? IEAO aeyaeythoue aioeaaie, ye?
aeni?aniaai? a iniiaiiio o i?ci?e G1, S oa I oacao ee?oeiiiai oeeeeo. A
ca‘yceo c oeei ?aiiy G1 caeeoa?oueny iica aiae?cii, ui ? aaaeeeaei
iaaeie?eii oeeo IEAO.

Oiio noai?aiiy iiaeo IEAO aei aioeaai?a, ye? aeni?anothoueny i?ioyaii
anueiai ia??iaea ae?eaiiy ee?oeie, a oaeiae aea/aiiy iiaeeeaino?
aeei?enoaiiy ?o ii?o/ c ii?oieia?/ieie, oeeoio?i?/ieie oa ?ioiio?i?/ieie
iciaeaie aeey oa?aeoa?enoeee iaoieia?/ieo ee?oei oai?eo ia iooeeie
??cii? eieae?caoe?? ? ia?niaeoeaiith ? aeooaeueiith caaea/ath no/anii?
iieieia??.

Ca‘ycie ?iaioe c iaoeiaeie i?ia?aiaie, ieaiaie, oaiaie.

Aeena?oaoe?eia ?iaioa aeeiiaia o A?aeae?e? ?ioiioeeoio?i?? ?inoeoooo
aenia?eiaioaeueii? iaoieia??, iieieia?? ? ?aae?ia?ieia??
?i.?.?.Eaaaoeueeiai IAI Oe?a?ie ca?aeii c ieaiaie iaoeiai-aeine?aeii?
?iaioe ca oaiaie 0.69.05.02.01 Ae(n), oa 0194UO17021, oeo? i?iaeaie
2.28.2.8.

Iaoa ? caaea/? aeine?aeaeaiiy.

Iaoa ?iaioe iieyaaea o noai?aii? iiaeo ?aaaaio?a — iiiieeiiaeueieo
aioeo?e aei aioeaaio, ui aeni?ano?oueny o i?ie?oa?oth/eo ee?oeiao, a
oaeiae c‘ynoaaiiy iiaeeeaino? aeei?enoaiiy ?o aeey aea/aiiy ?
ae?aaiinoeee iooeei ethaeeie ??cii? eieae?caoe?? ? a?noieia?/ii?
no?oeoo?e.

Caaea/? aeine?aeaeaiiy:

1. Io?eiaiiy IEAO i?ioe yaea?iiai aioeaaio, yeee aeni?ano?oueny o
i?ie?oa?oth/eo ee?oeiao.

2. Aecia/aiiy niaoeeo?/iino? io?eiaieo IEAO c aeei?enoaiiyi e?i?e
ee?oei ??ciiai iioiaeaeaiiy, iiiiioeeaa??a ia?eoa?e/ii? e?ia?,
e?iaioai?ieo oa e?ioi?aeieo i?aai?a i?aeoe/ii caei?iaeo aeiii??a oa
oai?eo ia ??ci? oi?ie e?ioii?ie?oa?aoeaieo caoai?thaaiue, a oaeiae
e?einoaoieo c??c?a iooeei oa a?noieia?/ii iaci?iaieo oeaiei.

3. Oa?aeoa?enoeea aioeaaio, ui aeyaeythoue io?eiai? IEAO.

4. C‘ynoaaiiy iiaeeeaino? aeei?enoaiiy io?eiaieo iiiieeiiaeueieo
aioeo?e aeey ioe?iee ??aiy i?ie?oa?aoe?? ee?oei o neeaae? iooeei ??cii?
eieae?caoe??.

Iaoeiaa iiaecia iaea?aeaieo ?acoeueoao?a.

Aia?oa io?eiai? oa ioa?aeoa?eciaai? IEAO, ui iacaai? ?II-38, ye?
aeyaeythoue yaea?iee aioeaai, aeni?an?y eio?iai niinoa??aa?oueny o?eueee
o i?ie?oa?oth/eo ee?oeiao. Aeiaaaeaii, ui aioeaai, yeee ?ici?cia?oueny
IEAO ?II-38, ia ? ?aeaioe/iei ?ai?o iienaiei oeeeeicaeaaeiei aioeaaiai,
oaeei ye PCNA, Ki-67. Aeei?enoaiiy oeeo IEAO aea? iiaeeea?noue
oa?aeoa?ecoaaoe i?ie?oa?aoeaio aeoeai?noue iooeeiieo ee?oei.

I?aeoe/ia cia/aiiy iaea?aeaieo ?acoeueoao?a. Iieacaia iiaeeea?noue
aeei?enoaiiy aeuacacia/aieo aioeo?e aeey aecia/aiiy i?ie?oa?aoeaii?
aeoeaiino? ceiye?niio?ainoi?iiaaieo ee?oei iacaeaaeii a?ae eieae?caoe??
iooeeiiiai i?ioeano.

Iniaenoee aianie caeiaoaa/a.

Aeena?oaio aaciina?aaeiuei i?eeiaea o/anoue a io?eiaii? a?a?eaeiie, ui
nae?aoothoue IEAO ?II-38, a oaeiae o aea/aii? niaoeeo?/iino? oeeo IEAO ;
naiino?eii i?iaaea a?io?i?/i? oa ?ioiio?i?/i? aeine?aeaeaiiy, ye?
noinothoueny c‘ynoaaiiy i?e?iaee aioeaaio, ui aeyaeythoue IEAO ?II-38.
Iniiai? ?aea?, aeniiaee oa ?aeiiaiaeaoe?? ?ic?iaeai? ? ioi?ieai?
aeena?oaioii naiino?eii.

Ai?iaaoe?y ?acoeueoao?a aeena?oaoe??.

Iaoa??aee ?iaioe aoee i?aaenoaaeai? oa iaaiai?ai? ia ?? Iaoe?iiaeueiiio
eiia?an? iieiaeeo a/aieo-iaaeee?a Oe?a?ie (Ee?a, 1994), ?
iaoe?iiaeuei?e i?aeoe/i?e eiioa?aioe?? c i?iaeai A?E/NI?Ae (Ee?a, 1995);
VI International Workshop and Conference on Human Leucocyte
Differentiation Antigens (Eiaa, ssiiiey, 1996); 8th European Congress on
Biotechnology (Aoaeaiaoo, 1997).

Ioae?eaoe??. Ca iaoa??aeaie aeena?oaoe?? iioae?eiaaii 6 iaoeiaeo noaoae
a i?ia?aeieo oaoiaeo aeaeaiiyo, iaoa??aeao ? oacao 8 eiioa?aioe?e.

No?oeoo?a ? ianya aeena?oaoe??. Aeena?oaoe?eia ?iaioa ia? 132 noi??iee,
neeaaea?oueny ?c anooio, iaeyaeo e?oa?aoo?e, 6 ?icae?e?a c aiae?cii ?
ocaaaeueiaiiyie ?acoeueoao?a aeanieo aeine?aeaeaiue, aeniiae?a, nieneo
aeei?enoaii? e?oa?aoo?e (212 ia?oiaeaea?ae, c ieo oe?a?inueeith oa
?in?enueeith iiaaie — 24, ?iicaiieie iiaaie — 188). ?iaioa ?ethno?iaaia
18 ?enoieaie, 5 oaaeeoeyie.

CI?NO ?IAIOE

IAOA??AEE ? IAOIAeE AeINE?AeAEAIIss

Aeey io?eiaiiy iiiieeiiaeueieo aioeo?e ?II-38 aoa aeei?enoaiee iaoiae
niiaoe/ii? a?a?eaeecaoe? o iiiioa??, yeee cai?iiiioaaee Davidson, Gerald
(1977). Ee?oeiaie-ia?oia?aie i?e a?a?eaeecaoe? aoee ee?oeie ieoeii?
i??eiie P3-X63-Ag8.653A oa nieaiioeeoe ieo?-naiee e?i?? BALB/c, yeo
iiia?aaeiuei ?ioi?coaaee ee?oeiaie naeac?iee oai?iai ia
aieinaoiee?oeiiee eaeeic. ?ioi?caoe?th i?iaiaeeee o?e ?ace, aaiaey/e
aioo??oiuei/a?aaeiii ii 8o106 ee?oei c ?ioa?aaeii 30 aei?a, inoaiith
?ioi?caoe?th i?iaiaeeee o aaio ca 4 aei? aei i?iaaaeaiiy a?a?eaeecaoe? o
e?eueeino? 18o106 ee?oei. Niiaoe/io a?a?eaeecaoe?th ee?oei i?iaiaeeee ca
aeiiiiiaith 50% iie?aoeeaiae?eiey (iie.iana 2000). I?ney naeaeoe??
a?a?eaeii o na?aaeiaeu?, ui ai?uoaaei a?iienaioei, ai?iiioa?ei,
oei?aeei, eeiioaaiiy ? ?aeeiioaaiiy iaoiaeii e?i?ooth/eo ?icaaaeaiue,
aoei a?ae?a?aii ooai a?a?eaeieo ee?oei, ui i?iaeoeoaaee iiiieeiiaeuei?
aioeo?ea, iicia/ai? ye ?II-38. Aeine?aeaeaiiy aeeiiai? ?acii c e.a.i.
Neaei?aiei N.I., e.i.i. A?o?iaith I.I., e.a.i. Oeaiaoeueeith E.I. oa
e.a.i. Aa?aeiaith A.A.. Aeaeo?iiiii?e?ineii?/i? aeine?aeaeaiiy aeeiiai?
i?e o/ano? e.a.i. TH?/aiei I.A.

Aea/aiiy niaoeeo?/iino? IEAO i?iaiaeeee ia 11 ee?oeiieo e?i?yo
ethaeeie ??ciiai iioiaeaeaiiy, ui ai?uoaaee e?i?? A-ee?oeiiiai
iioiaeaeaiiy (Raji, Ramos), O-ee?oeii? (MOLT-4, Jurkat, CEM, HUT), e?i??
ee?oei iae?ioi?aeiiai iioiaeaeaiiy (K562, U-937, HL-60, MeWo, A-431), a
oaeiae aeaio e?i?yo ee?oei ieoae (L-929, OH-1); ia iiiiioeeaa?ao
ia?eoa?e/ii? e?ia? 5 i?aeoe/ii caei?iaeo ethaeae, 79 oai?eo ia ??ci?
oi?ie aaiiaeanoic?a, ee?oeiao e?ioiaoce?a 10 oai?eo ia iaoiaeaee?inuee?
ceiye?ni? e?ioiie ? 4 oai?eo ia e?ioia?aioeaiaoic. Aeey aiae?co aoei
aeei?enoaii iai?yiee aa??aio ?ioiioeoi?anoeaioiiai iaoiaea ia aeeaeo
ee?oeiao. Ae?aaiice eaeeic?a oa e?ioii aoee iinoaaeai? ia iniia?
noaiaea?oieo ii?oieia?/ieo, ee?i?/ieo oa oeeoio?i?/ieo e?eoa???a o
ni?a?ia?oieoeoa? c ae.i.i. E.I. Neey?aiei oa e.a.i. A.A. Iaaeai?iith i?e
eiinoeueoaoe?? ae.i.i., i?io. Ae.O. Aeociaia.

Aeey ?aeaioeo?eaoe?? i?ie?oa?aoeaiiai ioea ee?oei o neeaae? e?ioiaoce?a
i?e ?aaeoeai?e a?ia?ieac?? e?ioi?aeii? oeaieie, o?ii?/iiio
ianiaoeeo?/iiio e?ioaaeai?o?, i?e iaoiaeaee?inueeeo ceiye?nieo e?ioiiao,
a oaeiae iooeeiii? oeaieie o aeiaaeeao ?aeo oeoieo, ea?oeeiiie eeoa/ieea
iooeei iiei/ii? caeice aoei aeei?enoaii ?ioiia?noio?i?/iee IAI iaoiae
ia e??inoaoieo c??cao.

Aeey c‘ynoaaiiy iniaeeainoae aeni?an?? aioeaaia, ui ?ici?ciathoue IEAO
?II-38, a oiae? i?ia?an?? ee?oeiiiai oeeeeo aoee aeei?enoai? e?ioioeeoe
i?aeoe/ii caei?iaeo ethaeae, noeioeueiaai? ca aeiiiiiaith
o?oiaaiaaethoei?ia (Ling, 1968). Aeey a?aooaaiiy e?eueeino? ?II-38+
ee?oei a caeaaeiino? a?ae oace ee?oeiiiai oeeeea aoei aeei?enoaii
a?ia?aiao?e/ia AeIE/?II-38 oa?aoaaiiy (Darzynkiewicz Z., 1980).
?aaeoe?th a?aoiaoaaee ca aeiiiiiaith i?ioi/iiai oeeoiiao?a AON 3000, ui
caaacia/aiee a?aiiiaei eaca?ii 2025 (Spectra Phisics). ?acoeueoaoe
cia?aaeai? o aeaeyae? a?ia?aiao?e/ieo a?noia?ai. Eiaeiiai ?aco
a?aoiaoaaeinue ia iaio i?ae 50000 iiae?e. Aeine?aeaeaiy i?iaaaeaii ia
aac? eaai?aoi??? aaiaoieia?? ainieoaeth Haut Lebeque (Ai?aei, O?aioe?y).

Iieaeoey?io iano aioeaaia aoei aecia/aii ca aeiiiiiaith Western-blot
aiae?ca aeeiiaiiai i?ney i?iaaaeaiiy aeaeo?ioi?aca a iie?ae?eeai?aeiiio
aae? a i?enooiino? DS-Na c aeei?enoaiiyi e?cao?a ee?oei e?i?? Raji.

Oeeo?iaee iaoa??ae, ui i?aaenoaaeaiee o aeena?oaoe?ei?e ?iaio?,
i?aeeyaaa aa??aoe?eii-noaoenoe/i?e ia?iaoe? (Eai?inueeee E.N., 1964).

?ACOEUeOAOE AeINE?AeAEAIUe

Io?eiaiiy ooaio a?a?eaeieo ee?oei. Aeey io?eiaiiy
a?a?eaeiie-i?iaeooeaioa IEAO ?II-38 a yeino? iaoa??aea aeey ?ioi?caoe??
aoei aeei?enoaii ee?oeie oai?iai ia aieinaoiee?oeiiee eaeeic. I?e
a?a?eaeecaoe?? aaea /a?ac 5 oaeeei niinoa??aaeenue o?ni? eiioaeoe i?ae
ee?oeiaie i??eiie oa nieaiioeeoaie. Ieiueia aeioeeo i?e oeueiio
a?ae??ciyeanue a?ae oi/eiaiai ii?aeiaiiy iaia?ai aeaio ee?oei o e?eueeio
i?noeyo aei eiioaeoa iaia?ai c ?o /anoeiaei ?ic/eiaiiyi. I?e
iiaeaeueoiio ceeoo? oeeoiieacie ooai?thaaeenue aeaiyaea?i?
aaoa?iea??iie, ui ai?uoaaee yae?a e?ioioeeoa oa i??eiiii? ee?oeie O
oe?e eoeueoo?? oaeiae iiaeia aoei cono??oe a?a?eaei? ee?oeie oeia
e?ioioeeo-e?ioioeeo oa i??eiia-i??eiia. *a?ac 40 oaeeei
niinoa??aaeanue iayai?noue ae?enii a?a?eaeieo ee?oei — neiea??ii?a.

A ?acoeueoao? naeaeoe?? ci?oaii? eoeueoo?e ee?oei, ui i?iaeoeoaaee ? ia
i?iaeoeoaaee aioeo?ea o AAO oa AO na?aaeiaeuao, a oaeiae eeiioaaiiy ?
?aeeiioaaiiy iaoiaeii e?i?ooth/eo ?icaaaeaiue, aoei a?ae?a?aii eeii
a?a?eaeiie 7F10, ui i?iaeoeoaaea aioeo?ea, iicia/ai? ye ?II-38. Oe?
IEAO ?aaaoaaee c aioeaaiii ee?oei naeac?iee oai?iai ia aieinaoiee?oeiiee
eaeeic, e?euee?noue ?aaaoth/eo ee?oei noaiiaeea 85%. I?e oeueiio
niinoa??aaeanue ?aaeoe?y o aeaeyae? a?aioe, ui ciaoiaeeeenue o yae?ao.

Ee?oeie a?a?eaeiie 7F10 aeia?a ?inee o ieanoeeiaeo oeaeiiao, aea
ooai?thaaee u?eueiee iiiioa?, oa o aeaeyae? anoeeoe/ii? ??aeeie o
/a?aai?e ii?iaeiei? ieoae e?i?? BALB/c. Ia 3-4 aeiao eoeueoeaoaaiiy
nae?aoe?y IEAO ?II-38 noaiiaeea 15-20 iea ia 1 ie eoeueoo?aeueiiai
na?aaeiaeua. I?e ?ino? o aeaeyae? anoeeoo oeae iieaciee aeinyaaa 8 ia ia
1 ie anoeeoe/ii? ??aeeie.

Oeyoii ELISA oanoo c aeei?enoaiiyi aioe?aeeioei?/ieo ne?iaaoie,
etha‘ycii iaaeaieo Ee?iia?/ai A.A. (Oeaio?aeueiee IAe?
?aioaaiieia??-?aae?ieia?? IIC ?in??, Naieo-Iaoa?ao?a), aoei
anoaiiaeaii, ui aioeo?ea ?II-38 iaeaaeaoue aei ?ioiiaeiaoe?i?a eeano I.

Ca oeeoiii?oieia?/ieie iieacieeaie ee?oeie a?a?eaeiie 7F10 iaaaaeothoue
e?ioiaeanoe na?aaeiueiai ?ici??o c aenieei yaea?ii-oeeoiieaciaoe/iei
a?aeiioaiiyi, aacio?eueiith oeeoiieaciith, a?oaith no?oeoo?ith
o?iiaoeio. I?e oeeoio?i?/iiio aei?iaiaoaaii? ee?oei ia aeyaeaii
aeoeaiino? oa?iaio?a ia?ieneaeace oa eenei? oinoaoace. Aeoeai?noue
eenei? ianiaoeeo?/ii? anoa?ace cia/ii ieae/a, i?ae a ee?oeiao, ye? aoee
aeei?enoai? aeey a?a?eaeecaoe??. Iii??ia a?aioey?ia ?aaeoe?y ia
ianiaoeeo?/io symbol 97 \f «Symbol» \s 12 -iaoo?eaoeaoaoanoa?aco
caa?aaaeanue i?e ae?? ?ia?a?oi?a NaF, PAS-?aaeoe?y — iii??ii-aeeoocia.

Oa?aeoa?enoeea aioeaaia, ui ?ici?ciathoue IEAO ?II-38. Aeey
?aeaioeo?eaoe?? aioeaaia, ui eiai ?ici?ciathoue IEAO ?II-38, aoei
i?iaiae?ciaaii yaea?iee aeno?aeo ee?oei e?i?? Raji. A ?acoeueoao?
i?iaaaeaiiy Western-blot aiae?ca aoei c‘yniaaii, ui iieaeoey?ia iana
aioeaaia, ui ?ici?ciathoue aeine?aeaeoaai? IEAO, aei??aith? 14-16 kDa.

Aeey aea/aiiy oeeeeicaeaaeieo ci?i a aeni?an?? aioeaaia, ui
?ici?cia?oueny IEAO ?II-38, a yeino? iiaeae? ia?aoiaeo ee?oei ?c noaio
niieith (G0) aei i?ie?oa?aoeaiiai (G1, S, G2, M) aoei aeei?enoaii
e?ioioeeoe i?aeoe/ii caei?iaeo ethaeae, noeioeueiaai?
o?oiaaiaaethoei?iii i?ioyaii 0, 12, 18, 24, 36 oa 48 aiae; ?aaeoe?th
a?aooaoaaee ia i?ioi/iiio oeeoiiao??. ?acoeueoaoe aoee cia?aaeai? o
aeaeyae? a?ia?aiao?e/ieo a?noia?ai.

?en.1 yaey? niaith ??ci? a?ia?aiao?e/i? a?noia?aie, iaea?aeai? i?ney
iiaea?eiiai AeIE/?II-38 oa?aoaaiiy noeioeueiaaieo e?ioioeeo?a, ?
iieaco?, ui ee?oeie o noai? niieith, oiaoi o G0 oac?
ee?oeiiiai oeeeeo, ia

aeni?anothoue aeoacacia/aiee aioeaai. I?ney noeioeyoe?? i?ioyaii 12
aiaeei (ii/aoie G1 oace i?oioe/iiai oeeeeo) ee?oeie ii/eiathoue
aeni?anoaaoe aioeaai, yeee aeyaeythoue aioeo?ea ?II-38.

Aei??thaaiiyi ?ioaineaiino? oa?aoaaiiy ee?oei a oiae? i?ia?an??
ee?oeiiiai oeeeea aoei aeiaaaeaii, ui ??aaiue aeni?an?? aioeaaia, yeee
aeyaeythoue IEAO ?II-38, caeeoa?oueny iino?eiei acaeiaae G1, S oa G2 oac
oeeeeo, a o i?oic? ca?eueoo?oueny aei 400% a?ae aeo?aeiiai ??aiy.

Aeey aea/aiiy aeeiai?ee ci?i a aeni?an?? aioeaaio, ui eiai aeyaeythoue
aioeo?ea ?II-38, i?ae /an aoiaeaeaiiy aei G1 oace ee?oeiiiai oeeeeo aoei
aeei?enoaii ee?oeie e?i?? E562, ye? ia?iaethaaeenue eieoeai?aeii
(?aaaaio aeieo? ee?oeie o i?oic?), uia cao?eiaoe aoiaeaeaiiy ee?oei aei
G1 oace i?oioe/iiai oeeeeo. ?en. 2 yaey? niaith AeIE/?II-38
a?ia?aiao?e/i? a?noia?aie, ye? iienothoue aeni?an?th aioeaaia o ee?oeiao
/a?ac 0, 1, 2, 4, 6 oa 8 aiaeei i?ney aieeao eieoeai?aea. sse aeaeii c
oeueiai ?enoiea, e?euee?noue oa?aiaaieo ee?oei, ui ciaoiaeyoueny o G1
oac?, iinooiiai ciaioo?oueny, a oie /an ye e?euee?noue ?II-38+ ee?oei,
ui ciaoiaeyoueny o ?ioeo oacao ee?oeiiiai oeeeea, caeeoa?oueny
iino?eiith. C oeueiai iiaeia c?iaeoe aeniiaie, ui aioeo?ea ?II-38
oa?aothoue ee?oeie acaeiaae an??? G1 oace ee?oeiiiai oeeeea. Ca
aeiiiiiaith eiii‘thoa?iiai aiae?ca aoei a?aoiaaii e?euee?noue ?II-38+
ee?oei, ui ciaoiaeyoueny o G1 oac? ee?oeiiiai oeeeea. Aeey ii??aiyiiy
aiaeia?/iee aenia?eiaio aoei aeeiiaii c aeei?enoaiiyi IEAO E?-67, ye?
?ici?ciathoue aioeaai, ui ii/eia? aeni?anoaaoenue o i?ci?e G1 oac?
ee?oeiiiai oeeeeo. I?iaeaiiino?iaaii, ui i?ioeaio ?II-38+ ee?oei
iinooiiai ciaioo?oueny, o oie /an, ye e?euee?noue E?-67+ ee?oei a
?ioa?aae? 1-3 aiaeeie caeeoa?oueny iino?eiith.

Ianooiiei aoaiii noaei c‘ynoaaiiy, iane?eueee oe? aioeo?ea iiaeooue
aooe aeei?enoaieie aeey aeeoa?aioe?thaaiiy i?ie?oa?oth/eo ee?oei ? oeo,
ui ciaoiaeyoueny o noai? niieith. C oe??th iaoith aoei cae?eniaii
oa?aoaaiiy ee?oei e?noeiaiai iicieo i?aeoe/ii caei?iai? ethaeeie oa
oai?iai ia aino?ee e?ioiaeanoiee eaeeic, i?e/iio aiae?coaaeanue
iiioeyoe?y ee?oei o G0 oa G1 oacao ee?oeiiiai oeeeeo. sse iiaeia aa/eoe
c iiiiia?aiao?e/ieo a?noia?ai, i?eaaaeaieo ia ?en. 3, ?II-38 aeicaiey?
i?iaiaeeoe oaea aeeoa?aioe?thaaiiy ia a?aei?io a?ae ?ai?o a?aeiieo IEAO
E?-67 .

Oaeei /eiii, a ?acoeueoao? aeeiiaiiy oe??? /anoeie ?iaioe aoei
c‘yniaaii, ui IEAO ?II-38 ?ici?ciathoue aioeaai, a?aenooi?e o
ee?oeiao, ye? ciaoiaeyoueny o noai? niieith ? ii/eia? aeni?anoaaoenue o
?aii?e G1 oac? ee?oeiiiai oeeeeo.

Aea/aiiy niaoeeo?/iino? IEAO ?II-38 ia e?i?yo ee?oei ??ciiai
iioiaeaeaiiy, iiiiioeeaa?ao ia?eoa?e/ii? e?ia? i?aeoe/ii caei?iaeo
ethaeae ? oai?eo ia ??ci? oi?ie aaiiaeanoic?a, a oaeiae ia e??inoaoieo
c??cao iooeei ??cii? eieae?caoe??. Aeey aecia/aiiy niaoeeo?/iino? IEAO
?II-38 aoei aeei?enoaii 11 e?i?e ee?oei ethaeeie ??ciiai iioiaeaeaiiy
oa 2 e?i?? ee?oei ieoae. Aioeaai, ui aeyaeythoue IEAO ?II-38,
?icoaoiaaiee o aeaeyae? a?aioe o yae??. A ie?aieo ee?oeiao
niinoa??aa?oueny yne?aaa ?aaeoe?y ii an?e ee?oei?.

Aecia/aii, ui aioeaai, yeee aeyaeythoue aioeo?ea ?II-38, ia ? aeaei- oa
e?i?eiiniaoeeo?/iei, ine?eueee eiai aeni?an?th iiaeia niinoa??aaoe ia
ee?oeiao e?i?e ??ciiai iioiaeaeaiiy ye ethaeeie, oae ? ieoae. I?e
ca?eueoaii? aonoeie ee?oei a?aeaoaa?oueny ae/a?ioaaiiy ?inoiaeo
oaeoi??a, cieaeaiiy ?I, i?ie?oa?aoeaiee iioaioe?ae ee?oei aaeueio?oueny,
? aeni?an?y aioeaaio iaeaea ia niinoa??aa?oueny. I?e aeiaeaaaii?
na?aeiai eoeueoo?aeueiiai na?aaeiaeua a?aeaoaa?oueny iiiiaeaiiy
i?ie?oa?aoe?? ee?oei ? iaeii/aniaa ca?eueoaiiy ?II-38+ ee?oei. Io?eiai?
aeaii? aeaee iiaeeea?noue i?eionoeoe, ui IEAO ?II-38 ?ici?ciathoue
aioeaai, aeni?an?y yeiai caeaaeeoue a?ae i?ie?oa?aoeaiiai iioaioe?aea
ee?oei.

Niaoeeo?/i?noue IEAO ?II-38 aea/aeanue oaeiae ia iiiiioeeaa?ao
ia?eoa?e/ii? e?ia? oai?eo ia ??ci? oi?ie aaiiaeanoic?a. Ae?aaiice aoei
anoaiiaeaii ia iniia? ii?oieia?/ieo, oeeoio?i?/ieo ? ?ioiieia?/ieo
e?eoa???a. ?acoeueoaoe i?aaenoaaeai? a oaae.1.

I?a-A-aa??aio AEE aoei ae?aaiinoiaaii o 6 oai?eo, yeeo ?iciiae?eeee ia
aea? a?oie. A aeanoieo ee?oeiao ia?eoa?e/ii? e?ia? oai?eo ? a?oie
aeni?an?y aioeaaia, ui aeyaey?oueny IEAO ?II-38, aoea neaai ae?aaeaiith
? neeaaeaea 5-10% (3 oai?eo), a o oai?eo ?? a?oie (3 oai?eo)
e?euee?noue ?II-38+ ee?oei neeaaeaea 75-95%. Aaeeeo e?euee?noue ?II-38+
ee?oei (84%) aeyaeaii o 2 oai?eo ia c??eee A-AEE. O aeayeeo aeiaaeeao
O-AEE, i?i-A-AEE a?aei?/aii neaaeo ?aaeoe?th ee?oei iaoieia?/iiai eeiia
c IEAO ?II-38. Caaaeueia e?euee?noue iiceoeaii ?aaaoth/eo ee?oei i?e
oeeo aa??aioao AEE noaiiaeea 3-8%.

Oaaeeoey 1.

Aca?iiae?y IEAO ?II-38 c e?iaioai?ieie ee?oeiaie ia?eoa?e/ii? e?ia?
i?aeoe/ii caei?iaeo ethaeae oa oai?eo ia ??ci? oi?ie aaiiaeanoic?a.

Aaiiiiaoe/i? ee?oeie E?euee?noue ?II-38+ aeiaaee?a/caaaeueia e?euee?noue
aeiaaee?a E?euee?noue ?II-38+ ee?oei, %

Ee?oeie ia?eoa?e/ii? e?ia? i?aeoe/ii caei?iaeo aeiii??a

iiiiioeeaa?e

a?aioeioeeoe

Ee?oeie iaoe??io?a c ??cieie oi?iaie eaeeic?a

OEE

AEE

AEE

IO

AIE, I4

AIE, I5

AIE, I1, I2

Ee?oeie e?ioiaoce?a

EAI

ICE

0/5

0/5

14/19

25/34

3/3

0/2

9/9

4/4

8/8

4/4

10/10

0

0

11.0.-94.0

6.0-95.0

19.0-85.0

0

10.0-90.0

5.0-80.0

2.0-8.0

30.0-75.0

3.0-92.0

I?e aea/aii? ee?oei oai?eo c aeayeeie aa??aioaie AIE aeyaeaia
aaoa?iaaii?noue aeni?an?? aioeaaio, ui ?ici?ciathoue IEAO ?II-38, a
iaaeao eiaeiiai c aa??aio?a I1, I2, I4, I5. C aioeo?eaie ?aaaoaaee 2-8%
aeanoieo ee?oei oai?eo AIE (I1, I2); i?e aa??aio? AIIE (I4) e?euee?noue
?II-38+-ee?oei noaiiaeea 10-90%, a o aeiaaeeo AIiiE (I5)- 5-80%.

Ia iniia? ii?oieia?/ieo oa oeeoio?i?/ieo iniaeeainoae, ?ioiieia?/iiai
oaiioeia e?ioioeeo?a ia?eoa?e/ii? e?ia? oai?eo OEE, a oaeiae aeoiaey/e c
iniaeeainoae aeni?an?? aioeaaio, ui ?ici?ciathoue IEAO ?II-38, ?o
?iciiae?eeee ia aea? a?oie. Ia?oo a?oio neeaee 6 oai?eo, iaoieia?/i?
ee?oeie yeeo aoee i?aaenoaaeai? iaeeie oa na?aaei?ie e?ioioeeoaie c
aaeeeei yaea?ii-oeeoiieaciaoe/iei a?aeiioaiiyi, ui iathoue yae?i
cae?oaeaii? oi?ie, /anii c aeyieith. ?aaeoe?y ia eeneo oinoaoaco ?
ianiaoeeo?/io anoa?aco o oeeo ee?oeiao aoea iaaaoeaiith,
iii??ii-aeeoociith /e i?eei-a?aioey?iith, ui ? oa?aeoa?iith ?enith
A-e?ioioeeo?a, ye? ciaoiaeyoueny o ?aii?e aioeaaicaeaaei?e /e i?ci?e
aioeaaiiacaeaaei?e noaae?? aeeoa?aioe?thaaiiy. Oaiioei oaeeo ee?oei aoa
ianooiiei: HLA-DR+, CD5+, CD19+, CD20+, CD10- , cyIg-, sIg+.
Aeaeo?iiiii?e?ineii?/i? aeine?aeaeaiiy i?iaeaiiino?oaaee, ui a?eueo?noue
e?ioioeeo?a ia?eoa?e/ii? e?ia? oai?eo oe??? a?oie aoee i?aaenoaaeai?
iaeeie e?ioioeeoaie ie?oaei? oi?ie c iaaaeeeith e?euee?noth
i?e?iae?ino?a oeeoiieacie. Iaea?eueo oeiiaeie iniaeeainoyie ee?oei aoea
iaaaeeea e?euee?noue aaoa?io?iiaoeio, ia?aaaaeii ?icoaoiaaiiai a?ey
yaea?ii? iaia?aie; o aocueeiio ia?aeeo oeeoiieacie e?ioioeeo?a
ee?oeii? i?aaiaee ae?aaeai? neaai; a?aioey?iee aiaeiieaciaoe/iee
?aoeeoeoi i?aaenoaaeaiee a e?ioioeeoao 2-5 i?eeeie aac?eoeaie c
?eainiiaie ia iiaa?oi? iaia?ai. ?ieiee a iaaaeee?e e?eueeino?
e?ioioeeo?a cono??/aeenue ei?ioe? ?icoe?ai? eaiaeueoe? a?aioey?iiai
aiaeiieaciaoe/iiai ?aoeeoeoia.

Aeey ae?oai? a?oie oai?eo (8 oai?eo) oa?aeoa?iith aoea iayai?noue
e?ioioeeo?a c aeinoaoiuei aenieith nooi?iith ieaciaoecaoe?? oeeoiieacie.
O aaaaoueio e?ioioeeoao ciaeaeaii aenieo aeoeai?noue eenei? oinoaoace c
?iciiae?eaiiyi i?iaeoeoa o aeaeyae? iaeeie/ieo e?oiieo a?aioe ? iii??ia
aeoeai?noue ianiaoeeo?/ii? anoa?ace. Iaoieia?/i? ee?oeie oai?eo ae?oai?
a?oie aoee a?eueo c??eeie ? iaee ianooiiee oaiioei: HLA-DR+, CD5+,
CD19+, CD20+, CD10-, cyIg+, sIg+. ?acoeueoaoe aeaeo?iiiii?e?ineii?/ieo
aeine?aeaeaiue ii?oieia?? iaoieia?/ieo e?ioioeeo?a ae?oai? a?oie oai?eo
ia OEE aeicaieythoue aaaaeaoe oe? ee?oeie a?eueo aeeoa?aioe?eiaaieie.
ssae?i c aa?ii ae?aaeaiei aaoa?io?iiaoeiii caeiaei a?eueoo /anoeio
ee?oei. A oeeoiieaci?, ui i?noeoue iii??io e?euee?noue ?eainii,
aeae?eyany aeia?a ?icaeiooee a?aioey?iee aiaeiieaciaoe/iee ?aoeeoeoi,
i?aaenoaaeaiee aeiaaeie aocueeeie eaiaeueoeyie. Ieaciaoe/ia iaia?aia
e?ioioeeo?a oai?eo OEE ae?oai? a?oie, ye i?aaeei, ia aeaaeea ? iaea
??ciiiai?oi? ae?inoe c ??ciith aeiaaeeiith i?e?iai?neiie.

Aioeaai, ui aeyaey?oueny IEAO ?II-38, aeni?anoaaany a yae?ao cia/ii?
/anoeie oai?eo i?e ia?oiio aa??aio? OEE. Ee?oeie oai?eo i?e ae?oaiio
aa??aio? c oaiioeiii c??eeo A-e?ioioeeo?a, ui ciaoiaeyoueny ia i?ci?e
aioeaaicaeaaei?e noaae?? aeeoa?aioe?thaaiiy, ia ?aaaoaaee c IEAO ?II-38.
Oaeei /eiii, o oai?eo OEE anoaiiaeaii ei?aeyoe?th i?ae aeni?an??th
aioeaaio, ui eiai aeyaeythoue IEAO ?II-38, oa nooiaiai
aeeoa?aioe?thaaiiy ee?oei iaoieia?/iiai eeiia.

Anoaiiaeaii, ui a?eueo?noue ee?oei e?ia? oai?eo ia aieinaoiee?oeiiee
eaeeic aeni?ano? aioeaai, ui aeyaey?oueny IEAO ?II-38.

Ee?oeie, ui iiceoeaii ?aaaothoue c IEAO ?II-38, ciaeaeai? ? o oai?eo
ICE. Ii e?eueeino? ?II-38+ ee?oei ?o ?iciiae?eeee ia aea? a?oie. Aei ?
a?oie oa?eoee 4 oai?eo c e?euee?noth ?II-38+ ee?oei — 3-10%. O oie aea
/an ai?no iiceoeaii ?aaaoth/eo ee?oei o oai?eo ?? a?oie (6 oai?eo)
neeaaeaa 50-92%. Iaiaaii, oe? ?icoiaeaeaiiy iia‘ycai? c i?ie?oa?aoeaiith
aaoa?iaaii?noth o iaaeao ? i?ae a?noieia?/ieie a?oiaie ICE, ui aieeaa?
ia ia?aa?a caoai?thaaiiy. I?e ??cieo a?noieia?/ieo aa??aioao EAI o
iioeiaeaeaieo e?ioaoe/ieo aoceao a?aei?/aii aenieee ai?no (30-75%)
?II-38+ ee?oei.

Aeey i?aeoaa?aeaeaiiy oiai, ui aioeaai, yeee ?ici?ciathoue IEAO ?II-38,
ia ? oeaieiiniaoeeo?/iei, aoea aea/aia eiai aeni?an?y ia e??inoaoieo
c??cao iooeei ??cii? eieae?caoe??. Aeey oeueiai aoei aeei?enoaii
?ioiia?noio?i?/iee IAI iaoiae; ia?aeaeueii aiae?coaaeenue ee?oeie
a?noieia?/ii iaci?iaieo oeaiei.

I?e ?aaeoeai?e a?ia?ieac?? e?ioi?aeii? oeaieie, o?ii?/iiio
ianiaoeeo?/iiio e?ioaaeai?o?, a oaeiae i?e iaoiaeaee?inueeeo ceiye?nieo
e?ioiiao a?ey 89% ee?oei e?ioaoe/ieo aoce?a aeaaaee iiceoeaio ?aaeoe?th
c IEAO ?II-38. Oa?aiaaiee o ei?e/iaaee eie?? i?iaeoeo ?aaeoe?? aoa
eieae?ciaaiee o yae?ao.

I?e oa?aoaaii? iooeeiii? oeaieie iecueeiaeeoa?aioe?eiaaiiai caeicenoiai
?aea oeoiea cia/ia /anoeia ee?oei iiceoeaii ?aaaoaaea c IEAO ?II-38,
i?e/iio ?ioaineai?noue ?aaeoe?? ??cieeanue o ??cieo ae?eyieao.
Aeine?aeaeaiiy ii?iaeueii? neeciai? iaieiiee oeoieo i?iaeaiiino?oaaei
iacia/io e?euee?noue ?II-38+ ee?oei.

An? ceiye?niio?ainoi?iiaai? ai?oae?aeuei? ee?oeie o aeiaaeeo
iii??ii-aeeoa?aioe?eiaaiiai ?aeo eeoa/ieea aeaaaee iiceoeaio ?aaeoe?th c
IEAO ?II-38. O oie aea /an o?eueee iiiaeeiie? ee?oeie a?noieia?/ii
iaci?iaii? neeciai? iaieiiee i?yii? eeoee ?aaaoaaee c aeuacacia/aieie
aioeo?eaie.

I?e ?io?eueo?iaai?e oi?i? aaeaiiea?oeeiiie iiei/ii? caeice o yae?ao an?o
iooeeiieo ee?oei, ui neeaaeaee a?eueo?noue o oeueio aeiaaeeo,
niinoa??aaeanue yne?aai ae?aaeaia ?aaeoe?y c IEAO ?II-38. I?e
o?a?iaaeaiiiaoic? iiei/ii? caeice /anoeia ee?oei, aea ia an?, aoee
?II-38+. I?e aiae?c? a?noieia?/ii iaci?iaii? oeaieie iiei/ii? caeice
iiceoeaio ?aaeoe?th c IEAO ?II-38 iiaeia aoei niinoa??aaoe o?eueee o
ae?eyieao, aea a?aeaoaa?oueny iiiiaeaiiy ee?oei.

Aeniiaee

1. Ca aeiiiiiaith a?a?eaeiiii? oaoiieia?? io?eiai? IEAO ?II-38 i?ioe
aioeaaio i?ie?oa?oth/eo ee?oei, iieaeoey?ia iana yeiai aei??aith?
14-16kDa.

2. Aioeaai, ui ?ici?cia?oueny IEAO ?II-38, ia ? aeaei- ?
oeaieiiniaoeeo?/iei. Eiai aeni?an?y niinoa??aa?oueny o yae?ao ee?oei
e?i?e ??ciiai iioiaeaeaiiy; ??aaiue aeni?an?? caeaaeeoue a?ae aeoeaiino?
i?ie?oa?aoe??.

3. Anoaiiaeaii, ui aioeaai ?II-38 a?aenooi?e o ee?oeiao, ui
ciaoiaeyoueny o noai? niieith, ? ii/eia? aeni?anoaaoenue o ?aii?e G1
oac? ee?oeiiiai oeeeeo, aeinyaath/e iaeneioia o i?oic?. Oe? aeaii?
io?eiai? ca aeiiiiiaith i?ioi/ii? oeeoiiao??? ia aeanoo?ainoi?iiaaieo
oeyoii OAA iiiiioeeaa?ao ia?eoa?e/ii? e?ia? i?aeoe/ii caei?iaeo
aeiii??a.

4. Aioeaai a?aenooi?e o iiiiioeeaa?ao ? a?aioeioeeoao e?ia? i?aeoe/ii
caei?iaeo ethaeae. E?euee?noue ?II-38+ ee?oei i?e ??cieo aa??aioao
aino?eo eaeeic?a iaoiiaeaia i?ie?oa?aoeaiith aeoeai?noth eaeeicieo
ee?oei. I?e OEE anoaiiaeaia ei?aeyoe?y i?ae ??aiai aeni?an?? aioeaaio oa
nooiaiai aeeoa?aioe?thaaiiy iaoieia?/ieo ee?oei.

5. Aioeaai ?II-38 aeni?ano?oueny iooeeiieie ee?oeiaie iiaiooai?aiue
??cii? eieae?caoe??. Iaoieia?/ii iaci?iai? oeaieie a nai?e a?eueoino?
aoee ?II-38 — iaaaoeaieie.

6. IEAO ?II-38 iiaeooue aooe aeei?enoaieie aeey aecia/aiiy ioea
i?ie?oa?oth/eo ee?oei o neeaae? iooeei ??cii? eieae?caoe??.

NIENIE IIOAE?EIAAIEO IAOEIAEO I?AOeUe

1. Neaei?aiei N.I., Oeaiaoeeay E.I., Aao?iaa A.I., Aa?aeiaa A.A.,
TH?/aiei I.A., Eeaiiaa O.O., Ieoaeai N.A., Aa?aiaiei E.A., Aeociai Ae.O.
Iiiieeiiaeueiua aioeoaea EII-38 e yaea?iiio aioeaaio i?ieeoa?e?othueo
eeaoie // Yenia?ei. iieieiaey. — 1994. -O.16, ?2-3. — N.145-150.

2. Mikhalap S.V, Lopez F., Shlapatskaya L.N., Yurchenko O.V., Berdova
A.G., Gluzman D.F., Belloc F., Sidorenko S.P.. Monoclonal antibody
IPO-38 recognizes a novel nuclear antigen of proliferating cells//
Leucocyte Typing VI. — New York-London: Garland Publishing Inc. — 1997.
— P.609-610.

3. Sidorenko S.P., Chu G., Draves K.E., Pinchuk L.M., Mikhalap S.V.,
Shao S., Clark E.A. The IPO-3/SLAM surface molecule associates with
protein kinase activities and CD45 in B lymphocytes// Leucocyte Typing
VI. — New York-London: Garland Publishing Inc. — 1997. — P.584-585.

4. Gololobov G.V., Mikhalap S.V., Starov A.V., Kolesnikov A.F., Gabibov
A.G. DNA — Protein Complexes Natural Targets for DNA-Hydrolysing
Antibodies// Applied Biochemistry and Biotechnology. — 1994.- V.47,
?2-3. — P. 305-315.

5. Ieoaeai N.A., O?iiye A.I., Oeaiaoeeay E.I., Aa?aeiaa A.A., Aacuea
Ae.A., Aeociai Ae.O. Iieo/aiea e ia?ae/iay oa?aeoa?enoeea
iiiieeiiaeueiuo aioeoae EII-I6// Yenia?ei. iieieiaey. -1995.- O.17.,
?3.-N.242

6. Aa?aiaiei E.A., Ieoaeai N.A., Aeociai Ae.O., Neiiiy I., Ioooy A.
Aiiioic eeioioeeoia ia?eoa?e/aneie e?iae /aeiaaea i?e aicaeaenoaee
iaeuo aeic ?aaeeaoeee// Yenia?ei. iieieiaey. -1995.- O.17, ?3.-N.241

7. Lopez F., Mikhalap S., Belloc F., Lacombe F., Gluzman D., Comparison
of three monoclonal antibodies (Ki-67, MIB1, IPO-38) for flow cytometric
identification of proliferating cells// Biol Cell. -1994. — V.79 —
P.234-235

8. Oeaiaoeueea E.I., I?oaeai N.A. Iiiieeiiaeuei? aioeo?ea na??? ?II a
ae?aaiinoeoe? ceiye?nieo caoai?thaaiue e?ia? ? ueoiaeaeii?
caeice//Oac.aeii. ?? Iaoe?iiaeueiiai Eiia?ano iieiaeeo a/aieo-iaaeee?a
Oe?a?ie. 18-19 o?aaiy 1994.- Ee?a- 1994. — N.12.

9. Aeociai, Ae.O., Aao?iaa, I.I., Neaei?aiei, N.I., Aa?aeiaa, A.A.,
I?oaeai, N.A. Iia? iiiieeiiaeuei? aioeo?ea aeey aea/aiiy
?ioiiiaoiaaie/ieo iaoai?ci?a A?E-?ioaeoe??.// Ca.oac. ? Iaoe.
Iaoe.-i?aeo. Eiioa? c i?iae. A?E/NI?Ae.- 1995. — N.85-86.

10. Mikhalap S.V., Shlapatskaya L.N., Yurchenko O.V., Berdova A.G.,
Gluzman D.F., Sidorenko S.P. Monoclonal antibody IPO-38 recognizes a
novel nuclear antigen of proliferating cells// Tissue Antigens.- 1996.
— V.48- P.461.

11. Sidorenko S.P., Chu G., Draves K.E., Pinchuk L.M., Mikhalap S.V.,
Shao S., Clark E.A. The IPO-3/SLAM surface molecule associates with
protein kinase activities and CD45 in B lymphocytes// Tissue Antigens.-
1996.- V.48- P.373.

12. Mikhalap, S.V., Lopez F., Shla?atskaya L.N., Yurchenko, O.V.,
Gluzman D.F., Sidorenko, S.P. IPO-38 a new monoclonal antibody against
nuclear antigan of proliferating cells//8th European congress on
Biotechnology.-1997. — P.97

13. Berdova A.G., Shlapatskaya L.N., Yurchenko, O.V., Mikhalap, S.V.,
Gluzman, D.F., Sidorenko, S.P. The panel of monoclonal antibodies of
IPO-series in human leukemia and lymphoma immunodiagnosis/8th European
congress on Biotechnology.-1997. — P.97

14. Shlapatskaya L.N., Berdova A.G., Mikhalap S.V., Yurchenko O.V.,
Gluzman D.F., Clark E.A., Sidorenko S.P. Expression of lymphocyte
activation antigens in human leukemias and lymphomas//Immunology
letters. — 1997.- V.56, ?1-3. — P.324.

AIIOAOe?ss

I?oaeai N.A. Iia? iiiieeiiaeuei? aioeo?ea ?II-38 aei yaea?iiai aioeaaio,
ui anioe?eiaaiee c i?ie?oa?aoe??th ii?iaeueieo oa
ceiye?niio?ainoi?iiaaieo ee?oei. -?oeiien.

Aeena?oaoe?y ia caeiaoooy iaoeiaiai nooiaiy eaiaeeaeaoa a?ieia?/ieo
iaoe ca niaoe?aeuei?noth 14.01.07 — iieieia?y, ?inoeooo
aenia?eiaioaeueii? iaoieia??, iieieia?? ? ?aae?ia?ieia??
?i.?.?.Eaaaoeueeiai IAI Oe?a?ie, Oe?a?inueeee iaoeiai-aeine?aeiee
?inoeooo iieieia?? oa ?aae?ieia?? IIC Oe?a?ie, Ee?a, 1998.

Oeyoii niiaoe/ii? a?a?eaeecaoe?? ee?oei io?eiaii a?a?eaeiio, ui
i?iaeoeo? iiiieeiiaeuei? aioeo?ea ?II-38 (IgM). Aeiaaaeaii, ui oe? IEAO
?ici?ciathoue yaea?iee aioeaai iieaeoey?ia iana yeiai noaiiaeoue 14-16
kDa. Anoaiiaeaii, ui aioeaai a?aenooi?e o ee?oeiao, ui ciaoiaeyoueny o
noai? niieith, ? ii/eia? aeni?anoaaoenue o ?aii?e G1 oac? ee?oeiiiai
oeeeeo, aeinyaath/e iaeneioia o i?oic?. Iniaeeaino? aeni?an?? aioeaaio
aoei aea/aii ia e?i?yo ee?oei ??ciiai iioiaeaeaiiy, iiiiioeeaa?ao
ia?eoa?e/ii? e?ia? i?aeoe/ii caei?iaeo ethaeae oa oai?eo ia ??ci? oi?ie
aaiiaeanoic?a, e??inoaoieo c??cao iooeei ??cii? eieae?caoe?? oa
a?noieia?/ii iaci?iaieo oeaiei. I?iaeaiiino?iaaii, ui aioeaai, yeee
?ici?ciathoue IEAO ?II-38, ia ? aeaei- ? oeaieiiniaoeeo?/iei,
?ioaineai?noue aeni?an?? caeaaeeoue a?ae i?ie?oa?aoeaiiai iioaioe?aea
ee?oei.

Eeth/ia? neiaa: iiiieeiiaeuei? aioeo?ea, i?ie?oa?aoe?y, oeeeeicaeaaei?
aioeaaie.

AIIIOAOeEss

Ieoaeai N.A. Iiaua iiiieeiiaeueiua aioeoaea EII-38 e yaea?iiio
aioeaaio, annioeee?iaaiiiio n i?ieeoa?aoeeae ii?iaeueiuo e
ceiea/anoaaiiio?ainoi?ie?iaaiiuo eeaoie.

Aeenna?oaoeey ia nieneaiea o/aiie noaiaie eaiaeeaeaoa aeieiae/aneeo
iaoe ii niaoeeaeueiinoe 14.01.07. — iieieiaey, Einoeooo
yenia?eiaioaeueiie iaoieiaee, iieieiaee e ?aaeeiaeieiaee
ei.?.A.Eaaaoeeiai IAI Oe?aeiu, Oe?aeineee iao/ii-enneaaeiaaoaeueneee
einoeooo iieieiaee e ?aaeeieiaee IC Oe?aeiu, Eeaa, 1998.

Iooai niiaoe/aneie aea?eaeecaoeee eeaoie iieo/aia aea?eaeiia,
i?iaeooee?othuay iiiieeiiaeueiua aioeoaea EII-38. Aeieacaii, /oi yoe
IEAO ?aniiciatho yaea?iue aioeaai, iieaeoey?iay ianna eioi?iai
ninoaaeyao 14-16kDa. Onoaiiaeaii, /oi aioeaai ionoonoaoao a iieiyueony
eeaoeao e ia/eiaao yenianne?iaaoueny a ?aiiae G1 oaca eeaoi/iiai oeeeea,
aeinoeaay iaeneioia a ieoica. Niaoeeoe/iinoue IEAO EII-38 eco/aeanue ia
eeieyo eeaoie ?aciiai i?ienoiaeaeaiey, iiiiioeeaa?ao ia?eoa?e/aneie
e?iae i?aeoe/anee caei?iaeo ethaeae e aieueiuo n ?acee/iuie oi?iaie
aaiiaeanoicia, ia e?einoaoiuo n?acao iiooieae ?acee/iie eieaeecaoeee e
aenoieiae/anee iaeciaiaiiuo oeaiae. I?iaeaiiino?e?iaaii, /oi aioeaai,
?aniiciaaaaiue IEAO EII-38, ia yaeyaony aeaei- e oeaianiaoeeoe/aneei,
eioaineaiinoue aai yeni?annee caaeneo io i?ieeoa?aoeaiiai iioaioeeaea
eeaoie.

Eeth/aaua neiaa: iiiieeiiaeueiua aioeoaea, i?ieeoa?aoeey,
oeeeeicaaeneiua aioeaaiu.

SUMMARY

Mikhalap S.V. New monoclonal antibody IPO-38 recognizing a nuclear
antigen associated with proliferation of normal and malignant cells.

Thesis for degree of candidate of biological sciences on speciality
14.01.07 — oncology, R.E.Kavetsky Institute of Experimental Pathology
Oncology and Radiobiology NAS of Ukraine, Institute of Oncology and
Radiology Ministry of Health Care of Ukraine, Kyiv, 1998.

Hybridoma-producing monoclonal antibody (mAb) IPO-38 (IgM) has been
developed following somatic hybridization technique. Mab IPO-38
recognizes an antigen of molecular weight 14000-16000. It was
indicated, that antigen is absent in nonproliferating cells and became
detectable in G1 phase of the cell cycle. The specificity of antigen
expression was studied on cell lines of different origin, mononuclears
isolated from peripheral blood of healthy persons and patients with
different hematological malignancies, cryostat section of different
tumors and normal tissues. It was shown that antigen, recognized with
mAb IPO-38 is not species- and tissuespecific, the expression intense
depends on proliferating potential of cells.

Key words: monoclonal antibody, proliferation, cell cycle dependent
antigens.

page 12

DATE 01/19/99

Добавить комментарий

Ваш e-mail не будет опубликован. Обязательные поля помечены *